Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
QuintilesIMS
US Department of Justice
Federal Trade Commission
Chinese Patent Office

Generated: September 20, 2019

DrugPatentWatch Database Preview

Dacomitinib - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for dacomitinib and what is the scope of dacomitinib patent protection?

Dacomitinib is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dacomitinib has fifty patent family members in forty-two countries.

Two suppliers are listed for this compound.

Summary for dacomitinib
International Patents:50
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 66
Clinical Trials: 24
Patent Applications: 2
DailyMed Link:dacomitinib at DailyMed
Synonyms for dacomitinib
(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
(2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
(E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
1006885-28-4
1110813-31-4
1110813-31-4 pound not PF 299804 pound not PF-299804
2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-
2XJX250C20
AB0035896
ABP000126
AC-25915
AKOS025401818
AOB87383
AOB87735
BC261945
BCP02530
BDBM112499
C24H25ClFN5O2
CHEBI:132268
CHEBI:91466
CHEMBL2110732
CS-0500
D06XXH
D09883
D5450
Dacomitinib (PF299804, PF-00299804)
Dacomitinib (PF299804, PF299)
Dacomitinib (USAN/INN)
Dacomitinib [USAN:INN]
Dacomitinib anhydrous
Dacomitinib, PF299804
dacomitinibum
DB11963
DTXSID50149493
EX-A030
GTPL7422
HY-13272
J-500784
KB-76397
MLS006011275
MolPort-023-293-536
NCGC00263185-09
PF 00299804
PF 00299804-03
PF-00299804
PF-00299804 dacomitinib
PF-00299804-03
PF-299
PF-299804
PF-299804 (Dacomitinib PF-00299804)
pf00299804
PF299
PF299804
PF299804|||PF299
Q-4059
QCR-174
RL00451
s2727
SC-94589
SMR004703025
UNII-2XJX250C20
US8623883, No. 2
Y0338
ZINC72266312

US Patents and Regulatory Information for dacomitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Merck
Fish and Richardson
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.